Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas

Meningiomas are the most common type of intracranial brain tumors in adults. The majority of meningiomas are benign with a low risk of recurrence after resection. However, meningiomas defined as grades II or III, according to the 2016 World Health Organization (WHO) classification, termed high-grade...

Full description

Bibliographic Details
Main Authors: Yukiko Nakahara, Hiroshi Ito, Jun Masuoka, Tatsuya Abe
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/12/5/1334
_version_ 1797567174182699008
author Yukiko Nakahara
Hiroshi Ito
Jun Masuoka
Tatsuya Abe
author_facet Yukiko Nakahara
Hiroshi Ito
Jun Masuoka
Tatsuya Abe
author_sort Yukiko Nakahara
collection DOAJ
description Meningiomas are the most common type of intracranial brain tumors in adults. The majority of meningiomas are benign with a low risk of recurrence after resection. However, meningiomas defined as grades II or III, according to the 2016 World Health Organization (WHO) classification, termed high-grade meningiomas, frequently recur, even after gross total resection with or without adjuvant radiotherapy. Boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) are novel treatment modalities for malignant brain tumors, represented by glioblastomas. Although BNCT is based on a nuclear reaction and PDT uses a photochemical reaction, both of these therapies result in cellular damage to only the tumor cells. The aim of this literature review is to investigate the possibility and efficacy of BNCT and PDT as novel treatment modalities for high-grade meningiomas. The present review was conducted by searching PubMed and Scopus databases. The search was conducted in December 2019. Early clinical studies of BNCT have demonstrated activity for high-grade meningiomas, and a phase II clinical trial is in progress in Japan. As for PDT, studies have investigated the effect of PDT in malignant meningioma cell lines to establish PDT as a treatment for malignant meningiomas. Further laboratory research combined with proper controlled trials investigating the effects of these therapies is warranted.
first_indexed 2024-03-10T19:38:52Z
format Article
id doaj.art-a53bbd848e2c41e08544e0ce6cdd7894
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-10T19:38:52Z
publishDate 2020-05-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-a53bbd848e2c41e08544e0ce6cdd78942023-11-20T01:30:09ZengMDPI AGCancers2072-66942020-05-01125133410.3390/cancers12051334Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade MeningiomasYukiko Nakahara0Hiroshi Ito1Jun Masuoka2Tatsuya Abe3Department of Neurosurgery, Faculty of Medicine, Saga University, Saga 840-8501, JapanDepartment of Neurosurgery, Faculty of Medicine, Saga University, Saga 840-8501, JapanDepartment of Neurosurgery, Faculty of Medicine, Saga University, Saga 840-8501, JapanDepartment of Neurosurgery, Faculty of Medicine, Saga University, Saga 840-8501, JapanMeningiomas are the most common type of intracranial brain tumors in adults. The majority of meningiomas are benign with a low risk of recurrence after resection. However, meningiomas defined as grades II or III, according to the 2016 World Health Organization (WHO) classification, termed high-grade meningiomas, frequently recur, even after gross total resection with or without adjuvant radiotherapy. Boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) are novel treatment modalities for malignant brain tumors, represented by glioblastomas. Although BNCT is based on a nuclear reaction and PDT uses a photochemical reaction, both of these therapies result in cellular damage to only the tumor cells. The aim of this literature review is to investigate the possibility and efficacy of BNCT and PDT as novel treatment modalities for high-grade meningiomas. The present review was conducted by searching PubMed and Scopus databases. The search was conducted in December 2019. Early clinical studies of BNCT have demonstrated activity for high-grade meningiomas, and a phase II clinical trial is in progress in Japan. As for PDT, studies have investigated the effect of PDT in malignant meningioma cell lines to establish PDT as a treatment for malignant meningiomas. Further laboratory research combined with proper controlled trials investigating the effects of these therapies is warranted.https://www.mdpi.com/2072-6694/12/5/1334boron neutron capture therapyphotodynamic therapymeningioma
spellingShingle Yukiko Nakahara
Hiroshi Ito
Jun Masuoka
Tatsuya Abe
Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas
Cancers
boron neutron capture therapy
photodynamic therapy
meningioma
title Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas
title_full Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas
title_fullStr Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas
title_full_unstemmed Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas
title_short Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas
title_sort boron neutron capture therapy and photodynamic therapy for high grade meningiomas
topic boron neutron capture therapy
photodynamic therapy
meningioma
url https://www.mdpi.com/2072-6694/12/5/1334
work_keys_str_mv AT yukikonakahara boronneutroncapturetherapyandphotodynamictherapyforhighgrademeningiomas
AT hiroshiito boronneutroncapturetherapyandphotodynamictherapyforhighgrademeningiomas
AT junmasuoka boronneutroncapturetherapyandphotodynamictherapyforhighgrademeningiomas
AT tatsuyaabe boronneutroncapturetherapyandphotodynamictherapyforhighgrademeningiomas